A Dose-ranging Study in Patients With Diabetic Peripheral Neuropathic Pain (DPNP)

Inclusion Criteria

• •1. Participant has given written informed consent to participate in the study in accordance with local regulations
• •2. Adult male and female participants ≥18 years of age at the Screening Visit
• •3. Body mass index ≥18.0 to ≤40.0 kilogram per meter square (kg/m\^2) at Screening
• •4. Diagnosis of type 1 diabetes mellitus (T1DM) or type 2 diabetes mellitus (T2DM) with chronic DPNP, at Screening
• •5. Pain from DPNP present for at least 6 months prior to Screening
• •6. At the Screening Visit, glycosylated hemoglobin (A1C) must be ≤11%.
• •7. Stable regimen for the treatment of T1DM or T2DM for ≥3 months prior to Screening
• •8. Willing to adhere to the prohibitions and restrictions specified in the protocol.